PARP1 and cancer: In terms of the importance of HR-mediated repair in PARP inhibitor sensitivity, our data indicate that mTORC2 is a druggable HR-mediated repair modulator and that mTORC2 inhibition leads to a BRCAness phenotype in cancer cells.